Matches in SemOpenAlex for { <https://semopenalex.org/work/W3176602365> ?p ?o ?g. }
- W3176602365 endingPage "742" @default.
- W3176602365 startingPage "733" @default.
- W3176602365 abstract "<h2>Summary</h2><h3>Background</h3> Non-steroidal anti-inflammatory drugs (NSAIDs), intravenous fluid, pancreatic stents, or combinations of these have been evaluated in randomised controlled trials (RCTs) for the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis, but the comparative efficacy of these treatments remains unclear. Our aim was to do an exploratory network meta-analysis of previous RCTs to systematically compare the direct and indirect evidence and rank NSAIDs, intravenous fluids, pancreatic stents, or combinations of these to determine the most efficacious method of prophylaxis for post-ERCP pancreatitis. <h3>Methods</h3> We searched PubMed, Embase, and the Cochrane Central Register from inception to Nov 15, 2020, for full-text RCTs that evaluated the efficacy of NSAIDs, pancreatic stents, intravenous fluids, or combinations of these for post-ERCP pancreatitis prevention in adult (aged ≥18 years) patients undergoing ERCP. Summary data from intention-to-treat analyses were extracted from published reports. We analysed incidence of post-ERCP pancreatitis across studies using network meta-analysis under the frequentist framework, obtaining pairwise odds ratios (ORs) and 95% CIs. We used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system for the confidence rating. This study is registered with PROSPERO, CRD42020172606. <h3>Findings</h3> We identified 1503 studies, of which 55 RCTs evaluating 20 interventions in 17 062 patients were included in the network meta-analysis. The mean incidence of post-ERCP pancreatitis in the placebo or active control group was 12·2% (95% CI 11·4–13·0). Normal saline plus rectal indometacin (OR 0·02, 95% CI 0·00–0·40), intramuscular diclofenac 75 mg (0·24, 0·09–0·69), intravenous high-volume Ringer's lactate plus rectal diclofenac 100 mg (0·30, 0·16–0·55), intravenous high-volume Ringer's lactate (0·31, 0·12–0·78), 5–7 Fr pancreatic stents (0·35, 0·26–0·48), rectal diclofenac 100 mg (0·36, 0·25–0·52), 3 Fr pancreatic stents (0·47, 0·26–0·87), and rectal indometacin 100 mg (0·60, 0·50–0·73) were all more efficacious than placebo for preventing post-ERCP pancreatitis in pairwise comparisons. 5–7 Fr pancreatic stents (0·59, 0·41–0·84), intravenous high-volume Ringer's lactate plus rectal diclofenac 100 mg (0·49, 0·26–0·94), intravenous standard-volume normal saline plus rectal indometacin 100 mg (0·04, 0·00–0·66), and rectal diclofenac 100 mg (0·59, 0·40–0·89) were more efficacious than rectal indometacin 100 mg. The GRADE confidence rating was low to moderate for 98·3% of the pairwise comparisons. <h3>Interpretation</h3> This systematic review and network meta-analysis summarises the available literature on NSAIDs, pancreatic stents, intravenous fluids, or combinations of these for prophylaxis of post-ERCP pancreatitis. Rectal diclofenac 100 mg is the best performing rectal NSAID in this network meta-analysis. Combinations of prophylaxis might be more effective, but there is little evidence. These findings help to establish prophylaxis of post-ERCP pancreatitis for future research and practice, and could reduce costs and increase adoption of prophylaxis. <h3>Funding</h3> None." @default.
- W3176602365 created "2021-07-05" @default.
- W3176602365 creator A5002721909 @default.
- W3176602365 creator A5003062527 @default.
- W3176602365 creator A5003430702 @default.
- W3176602365 creator A5038843628 @default.
- W3176602365 creator A5041026404 @default.
- W3176602365 creator A5041561606 @default.
- W3176602365 creator A5042385064 @default.
- W3176602365 creator A5051721587 @default.
- W3176602365 creator A5054206779 @default.
- W3176602365 creator A5064304774 @default.
- W3176602365 creator A5065300274 @default.
- W3176602365 creator A5066903532 @default.
- W3176602365 creator A5069787247 @default.
- W3176602365 creator A5072837175 @default.
- W3176602365 creator A5075107428 @default.
- W3176602365 creator A5079444285 @default.
- W3176602365 creator A5085267958 @default.
- W3176602365 creator A5086048979 @default.
- W3176602365 date "2021-09-01" @default.
- W3176602365 modified "2023-09-29" @default.
- W3176602365 title "Non-steroidal anti-inflammatory drugs, intravenous fluids, pancreatic stents, or their combinations for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a systematic review and network meta-analysis" @default.
- W3176602365 cites W1495967812 @default.
- W3176602365 cites W1532943135 @default.
- W3176602365 cites W1582733805 @default.
- W3176602365 cites W1964244612 @default.
- W3176602365 cites W1969178574 @default.
- W3176602365 cites W1978775180 @default.
- W3176602365 cites W1981026485 @default.
- W3176602365 cites W1991348220 @default.
- W3176602365 cites W2010699829 @default.
- W3176602365 cites W204046373 @default.
- W3176602365 cites W2043813971 @default.
- W3176602365 cites W2074147400 @default.
- W3176602365 cites W2085803274 @default.
- W3176602365 cites W2089115083 @default.
- W3176602365 cites W2091833465 @default.
- W3176602365 cites W2100650200 @default.
- W3176602365 cites W2103377881 @default.
- W3176602365 cites W2111022944 @default.
- W3176602365 cites W2113464825 @default.
- W3176602365 cites W2116827291 @default.
- W3176602365 cites W2121796373 @default.
- W3176602365 cites W2125435699 @default.
- W3176602365 cites W2131774959 @default.
- W3176602365 cites W2144625636 @default.
- W3176602365 cites W2145758369 @default.
- W3176602365 cites W2157134953 @default.
- W3176602365 cites W2237437504 @default.
- W3176602365 cites W2296083992 @default.
- W3176602365 cites W2443235710 @default.
- W3176602365 cites W2464924628 @default.
- W3176602365 cites W2512631225 @default.
- W3176602365 cites W2546501065 @default.
- W3176602365 cites W2554196773 @default.
- W3176602365 cites W2558697804 @default.
- W3176602365 cites W2606304149 @default.
- W3176602365 cites W2609777439 @default.
- W3176602365 cites W2737074968 @default.
- W3176602365 cites W2764275027 @default.
- W3176602365 cites W2771999276 @default.
- W3176602365 cites W2805123749 @default.
- W3176602365 cites W2823781640 @default.
- W3176602365 cites W2894278684 @default.
- W3176602365 cites W2933878882 @default.
- W3176602365 cites W2966038383 @default.
- W3176602365 cites W2996748935 @default.
- W3176602365 cites W2999304853 @default.
- W3176602365 cites W3005045388 @default.
- W3176602365 cites W3010033872 @default.
- W3176602365 cites W3015163167 @default.
- W3176602365 cites W3036926952 @default.
- W3176602365 cites W3139306446 @default.
- W3176602365 doi "https://doi.org/10.1016/s2468-1253(21)00170-9" @default.
- W3176602365 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34214449" @default.
- W3176602365 hasPublicationYear "2021" @default.
- W3176602365 type Work @default.
- W3176602365 sameAs 3176602365 @default.
- W3176602365 citedByCount "27" @default.
- W3176602365 countsByYear W31766023652021 @default.
- W3176602365 countsByYear W31766023652022 @default.
- W3176602365 countsByYear W31766023652023 @default.
- W3176602365 crossrefType "journal-article" @default.
- W3176602365 hasAuthorship W3176602365A5002721909 @default.
- W3176602365 hasAuthorship W3176602365A5003062527 @default.
- W3176602365 hasAuthorship W3176602365A5003430702 @default.
- W3176602365 hasAuthorship W3176602365A5038843628 @default.
- W3176602365 hasAuthorship W3176602365A5041026404 @default.
- W3176602365 hasAuthorship W3176602365A5041561606 @default.
- W3176602365 hasAuthorship W3176602365A5042385064 @default.
- W3176602365 hasAuthorship W3176602365A5051721587 @default.
- W3176602365 hasAuthorship W3176602365A5054206779 @default.
- W3176602365 hasAuthorship W3176602365A5064304774 @default.
- W3176602365 hasAuthorship W3176602365A5065300274 @default.
- W3176602365 hasAuthorship W3176602365A5066903532 @default.
- W3176602365 hasAuthorship W3176602365A5069787247 @default.
- W3176602365 hasAuthorship W3176602365A5072837175 @default.